UC San Diego School of Medicine researchers discovered gene expression patterns associated with pandemic viral infections, providing a map to help define patients’ immune responses, measure disease severity, predict outcomes and test therapies — for current and future pandemics.
David C. Fajgenbaum, MD, MBA, MSc, an assistant professor of Translational Medicine & Human Genetics and director of the Center for Cytokine Storm Treatment & Laboratory at the Perelman School of Medicine at the University of Pennsylvania, was awarded $1 million by the Parker Institute for Cancer Immunotherapy (PICI) to expand the scope of the COvid19 Registry of Off-label & New Agents (CORONA) project and build out his team to accelerate treatment identification for COVID-19.
A repurposed drug used to treat arthritis did not significantly improve the outcomes of patients with severe COVID-19 pneumonia. Tocilizumab did not significantly improve clinical status or mortality rate at 28 days for participants who received it compared to a placebo.
New research published ahead of print in the American Journal of Physiology-Cell Physiology explores the role of mitochondrial function and related metabolic changes in the inflammatory response seen in people with COVID-19, the disease caused by the SARS-CoV-2 virus. Dysfunction…
A study from researchers at Washington University School of Medicine in St. Louis and St. Jude Children’s Research Hospital in Memphis showed that, contrary to expectations, most people with severe COVID-19 do not suffer from unbridled inflammation. The findings suggest that anti-inflammatory therapies may not be helpful for most COVID-19 patients.
Researchers at Washington University School of Medicine in St. Louis have completed a clinical trial suggesting that the antidepressant drug fluvoxamine may help prevent deterioration in COVID-19 patients, making hospitalization less likely.
What about the kidneys make them a hotspot for COVID-19’s cytokine storm? A research team says it’s the presence of a protein found on specialized renal transport cells.
Like a cold front that moves in, setting the stage for severe weather, coronavirus infection triggers showers of infection-fighting immune molecules – showers that sometimes escalate into a chaotic immune response known as a cytokine storm.
Treatment with a peptide that mimics the naturally occurring protein GIV prevents immune overreaction and supports a mechanism critical for survival in mouse models of sepsis and colitis, according to a UC San Diego study.
Researchers have used “omics” data containing genetic profiles of drugs to identify the hormone oxytocin as a possible treatment for COVID-19, the disease caused by the novel coronavirus (SARS-CoV-2).
The University of Kansas Medical Center announced today a trial exploring a drug intended to fight the cytokine storm common in COVID-19.
A team of researchers led by neuroscientists at Harvard Medical School has successfully used acupuncture to tame cytokine storm in mice with systemic inflammation.
Critically ill COVID-19 patients who received a single dose of a drug that calms an overreacting immune system were 45% less likely to die overall, and more likely to be out of the hospital or off a ventilator one month after treatment, compared with those who didn’t receive the drug, according to a new observational study.
A new review details three distinct phases of COVID-19, the disease caused by the novel coronavirus SARS-CoV-2, and urges medical professionals to consider an individualized treatment approach based on the disease phases and each patient’s symptoms. The review is published ahead of print in Physiological Reviews.